Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

SLN - Silence Therapeutics Plc - ADR


IEX Last Trade
19.13
0.380   1.986%

Share volume: 79,571
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$18.75
0.38
2.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
17.84%
1 Month
-4.07%
3 Months
-12.47%
6 Months
-25.69%
1 Year
112.82%
2 Year
85.52%
Key data
Stock price
$19.13
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$6.15 - $27.72
52 WEEK CHANGE
$1.25
MARKET CAP 
571.330 M
YIELD 
N/A
SHARES OUTSTANDING 
29.928 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
BETA 
0.94
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$200,462
AVERAGE 30 VOLUME 
$279,311
Company detail
CEO: Craig A. Tooman
Region: US
Website: https://www.silence-therapeutics.com/
Employees: 111
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

silence therapeutics develops a new generation of medicines by harnessing the body’s natural mechanism of rna interference, or rnai, within its cells. our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic rna molecules exclusively to target cells. silence’s proprietary rna chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. for more information, visit us at www.silence-therapeutics.com

Recent news